✦ LIBER ✦

PCN7 COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER

✍ Scribed by B. Schwander; J. de Castro Carpeño; D.F. Heigener; E. Wright; H.G. Bischoff; S. Walzer

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN82 Cost-Effectiveness Analysis of Erl

✍ P. Garrido; G. López-Vivanco; R. Rosell; B. Espinós; A. Castro-Gomez 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCN100 COST-EFFECTIVENESS OF GEFITINIB V

✍ J Jacob; M Henriksson; D Brattström 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Influence of first-line chemotherapy and

✍ Wu, Jenn-Yu; Yu, Chong-Jen; Shih, Jin-Yuan; Yang, Chih-Hsin; Yang, Pan-Chyr 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 374 KB

PCN75 COST-EFFECTIVENESS ANALYSIS OF EGF

✍ O Arrieta; P Anaya; RJ López; AC Polanco 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

Erlotinib as first-line treatment of Eur

✍ Petruzelka, Lubos 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 43 KB

P-485 EGFR mutations do not accurately p

✍ Giaccone, G.; Janmaat, M.; Gallegos Ruiz, M.; Rodriguez, J.; LeChevalier, T.; Th 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 150 KB